Progesterone Resistance
7
2
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
Progesterone Supplementation in Threatened Abortion
Progesterone Action on Endometrium of PCOS
Step Down FSH Approach and Late Follicular Phase in Progesterone Level
Variation of Progesterone in IVF Cycles